Gilead Sciences (NASDAQ: GILD) took a hit a few weeks ago when healthcare provider Express Scripts (NASDAQ: ESRX) chose AbbVie’s (NYSE: ABBV) hepatitis C drug over …
In a research report published Tuesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on AbbVie (NYSE:ABBV) with an $80 price target, …
S&P Capital IQ, a leading provider of multi-asset class research data and insights, has announced the release of its review of 2014 Q3 …
Entry: $9.86 10/2/14 Take Profits: $14.
